| 6.68 0.72 (12.08%) | 10-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 13.99 |
1-year : | 16.34 |
| Resists | First : | 11.97 |
Second : | 13.99 |
| Pivot price | 6.59  |
|||
| Supports | First : | 4.71 |
Second : | 0.22 |
| MAs | MA(5) : | 6.27 |
MA(20) : | 7.1 |
| MA(100) : | 1.96 |
MA(250) : | 1.12 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 18.8 |
D(3) : | 12.1 |
| RSI | RSI(14): 59.6 |
|||
| 52-week | High : | 11.97 | Low : | 0.22 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GTBP ] has closed below upper band by 45.0%. Bollinger Bands are 26.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.68 - 6.72 | 6.72 - 6.75 |
| Low: | 5.86 - 5.89 | 5.89 - 5.92 |
| Close: | 6.62 - 6.68 | 6.68 - 6.73 |
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.
Tue, 29 Sep 2026
With $31.2M left to sell, GT Biopharma (GTBP) has made its first equity sale. - Stock Titan
Fri, 25 Sep 2026
GT Biopharma regains Nasdaq $1.00 minimum bid compliance after 10-day stretch - TradingView
Tue, 15 Sep 2026
New investor hits 9.99% ceiling in GT Biopharma (GTBP) - Stock Titan
Tue, 15 Sep 2026
GT Biopharma Raises $7.45 Million in Series M Preferred Offering With Warrants, Adds Greenshoe - TradingView
Fri, 11 Sep 2026
GT Biopharma to Host Live Company Presentation on the - GlobeNewswire
Fri, 14 Aug 2026
GT Biopharma Reports Second Quarter 2026 Financial Results - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 45 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 5.7 (%) |
| Held by Institutions | 4.6 (%) |
| Shares Short | 163 (K) |
| Shares Short P.Month | 191 (K) |
| EPS | 130.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.07 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -158.2 % |
| Return on Equity (ttm) | -113.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | 0.05 |
| PEG Ratio | 1 |
| Price to Book value | 83.5 |
| Price to Sales | 0 |
| Price to Cash Flow | -20.89 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|